227 institutions reported holding CLDX for 2026Q1, together 109% of the company, more than the 185 a quarter earlier. Institutions reporting a position: 227 (as of 2026Q1). Shares held by institutions: 72.6M, long US equity positions only, as reported on Form 13F. Reported value: $2.30B, at 2026-03-31 prices, not today's. Top 5 holders: 41%, of the whole company, between five filers.

CLDXCelldex Therapeutics, Inc.

HealthcareUSD

$40.57

$20.0152 weeks$44.88

Who owns CLDX

227 institutions reported holding CLDX for 2026Q1, together 109% of the company, more than the 185 a quarter earlier.

227

Institutions reporting a position · as of 2026Q1 · up from 185 the quarter before

Shares held by institutions: 72.6M
Shares held by institutions · 109% of the company · long US equity positions only, as reported on Form 13F
Reported value: $2.30B
Reported value · at 2026-03-31 prices, not today's
Top 5 holders: 41%
Top 5 holders · of the whole company, between five filers

Details›

Reporting quarter2026-03-31: 2026Q1
Quarters on record: 52
New positions: 54
Positions exited: 17
Added to: 67
Reduced: 56
Top 10 holdersof the company: 60%

Institutional ownership by quarter, 2013Q2 to 2026Q1
Quarter	Filers	Shares	Reported value
2026Q1	227	72.6M	$2.30B
2025Q4	185	73.0M	$1.98B
2025Q3	184	70.7M	$1.83B
2025Q2	179	72.3M	$1.47B
2025Q1	171	73.6M	$1.34B
2024Q4	173	73.7M	$1.86B
2024Q3	175	71.7M	$2.44B
2024Q2	181	69.5M	$2.57B
2024Q1	197	69.3M	$2.91B
2023Q4	163	61.0M	$2.42B
2023Q3	144	50.6M	$1.39B
2023Q2	150	50.2M	$1.70B
2023Q1	161	49.5M	$1.78B
2022Q4	167	48.7M	$2.17B
2022Q3	159	49.1M	$1.38B
2022Q2	155	48.0M	$1.29B

Largest reported holders, 2026Q1
Holder	Shares	% of company	Value
WELLINGTON MANAGEMENT GROUP LLP	8.6M	13%	$272M
Kynam Capital Management, LP	5.8M	8.8%	$185M
BlackRock Inc.	5.4M	8.1%	$170M
VANGUARD GROUP INC	4.1M	6.2%	$130M
FMR LLC	3.7M	5.6%	$119M
Point72 Asset Management, L.P.	3.2M	4.9%	$102M
STATE STREET CORP	2.8M	4.2%	$89M
Commodore Capital LP	2.7M	4.1%	$86M
PRICE T ROWE ASSOCIATES INC /MD/	2.1M	3.1%	$66M
Eversept Partners, LP	1.8M	2.7%	$57M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…

Biotechnology

Ranks #98 of 145 by Smart Score

Compare peers

KLRA-3.3%

Kailera Therapeutics, Inc.

IRON-0.30%

Disc Medicine, Inc.

TARS-4.1%

Tarsus Pharmaceuticals, Inc.

TRVI+2.7%

Trevi Therapeutics, Inc.

RARE+0.48%

Ultragenyx Pharmaceutical Inc.

VERA+2.5%

Vera Therapeutics, Inc.